- Home
- RCUS vs XERS Comparison
RCUS vs XERS Comparison
Compare RCUS & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCUS
- XERS
- Stock Information
- Founded
- RCUS 2015
- XERS 2005
- Country
- RCUS United States
- XERS United States
- Employees
- RCUS N/A
- XERS N/A
- Industry
- RCUS Biotechnology: Pharmaceutical Preparations
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- RCUS Health Care
- XERS Health Care
- Exchange
- RCUS Nasdaq
- XERS Nasdaq
- Market Cap
- RCUS 1.2B
- XERS 1.3B
- IPO Year
- RCUS 2018
- XERS 2018
- Fundamental
- Price
- RCUS $17.35
- XERS $9.20
- Analyst Decision
- RCUS Buy
- XERS Strong Buy
- Analyst Count
- RCUS 8
- XERS 7
- Target Price
- RCUS $26.50
- XERS $8.00
- AVG Volume (30 Days)
- RCUS 1.2M
- XERS 2.2M
- Earning Date
- RCUS 11-05-2025
- XERS 11-06-2025
- Dividend Yield
- RCUS N/A
- XERS N/A
- EPS Growth
- RCUS N/A
- XERS N/A
- EPS
- RCUS N/A
- XERS N/A
- Revenue
- RCUS $262,000,000.00
- XERS $246,025,000.00
- Revenue This Year
- RCUS N/A
- XERS $43.89
- Revenue Next Year
- RCUS N/A
- XERS $20.40
- P/E Ratio
- RCUS N/A
- XERS N/A
- Revenue Growth
- RCUS 6.07
- XERS 35.62
- 52 Week Low
- RCUS $6.50
- XERS $2.82
- 52 Week High
- RCUS $18.98
- XERS $9.49
- Technical
- Relative Strength Index (RSI)
- RCUS 64.78
- XERS 65.97
- Support Level
- RCUS $16.41
- XERS $8.99
- Resistance Level
- RCUS $18.42
- XERS $9.41
- Average True Range (ATR)
- RCUS 1.17
- XERS 0.41
- MACD
- RCUS 0.04
- XERS 0.05
- Stochastic Oscillator
- RCUS 75.30
- XERS 85.96
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).